GlassScriptPhysician profile
Leonid Zamdborg
NPI 1467899534
$6,780.60
in general payments reported to CMS, 2019-2025
63 companies · $2,364 in 2025
The $2,364 reported for 2025 was more than what 91% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $274 · 2022: $505 · 2023: $654 · 2024: $1,973 · 2025: $2,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,990.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $767.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $527.54 | 2019-2025 | Lynparza, Calquence, Tagrisso |
| Janssen Biotech, INC. | $444.31 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $338.83 | 2019-2025 | Keytruda, Keytruda Qlex, Lagevrio |
| Takeda Pharmaceuticals U.S.A., INC. | $327.74 | 2019-2025 | Alunbrig, Ninlaro, Iclusig |
| Lilly USA, LLC | $252.51 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $201.92 | 2024-2025 | Venclexta, Tecentriq, Itovebi |
| Incyte Corporation | $189.99 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $183.19 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Novocure INC. | $181.63 | 2024 | Optune |
| Eagle Pharmaceuticals, INC. | $168.09 | 2022-2024 | |
| Abbvie INC. | $159.74 | 2019-2025 | |
| Astellas Pharma US INC | $158.91 | 2019-2024 | Xtandi, Xospata, Padcev |
| Pfizer INC. | $150.90 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $127.06 | 2024-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Zamdborg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.